Company: APXIF
Filing Date: 2025-07-03
Form Type: F-4/A
Source: 0001213900-25-061545
Chunk: 361

Company: APx Acquisition Corp. I
Filing Date: 2025-07-03
Form: F-4/A
Chunk 361
---
 and services are developed based on user insights, local languages and cultures, operations and logistics requirements, and unmet market needs that we have identified. We have a track record that has allowed us to achieve product market fit with our services. As such, we believe OmnigenicsAI’s products can play a pivotal role in revolutionizing health management. • Adoption: we anticipate that, as we enhance our customer experience and the industry develops, more consumers will desire genetic tests and physicians will be open and more willing to incorporate genetic information into their practice. This is especially true in encouraging adoption among non -geneticexperts, who are often the initial contact for customers and patients in a health journey. Further, we expect to advance adoption of our products and services by publishing research and providing educational support, thus generating awareness on the benefits of genetic testing. • Developing Strategic Partnerships: we are committed to commercializing our products through the Americas, developing a range of key partnerships with laboratories, providers, payers, among other market players. We will continue to bolster our existing partnerships while also exploring new ones to enter new markets and develop new products. These include diagnostic laboratories through a consortium, pharmaceutical companies, biopharma partners, healthcare service providers and health systems, who face significant barriers such as lack of technology, lack of localized genomic databases, and expertise. • Lower cost: as we plan on continuing to expand our business and network, we expect to reduce our costs while continuing our pursuit of accessible prices to further increase our addressable market. We are poised to benefit from the ongoing reduction in genetic sequencing and data processing costs, which have decreased substantially in recent years and continue to trend downward. This decline has been driven by advancements in sequencing technology and bioinformatics, therefore making genetic testing more affordable and accessible to a broader population. According to industry public reports titled “DNA Sequencing Costs: Data”, published by National Human Genome Research Institute on May16, 2023, and “Cost of NGS”, published by Illumina in April 2023, the sequencing cost -per-genomehas decreased approximately 96% over the past ten years. We believe this downward trend increases the potential reach and penetration of our services in sizeable and underserved populations in a range of geographies. In addition, we expect that our business -to-business-to-consumerproduct distribution model will deliver greater market penetration at a lower cost when compared to our previous direct -to-consumermodel. • Sustainable and inclusive growth: we are committed to working with all of our strategic partners